Ovid Therapeutics Inc.

As of June 30, 2026, Ovid Therapeutics Inc. carries a market capitalization of 439.72M, placing it among publicly traded companies globally. Its enterprise value stands at 348.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ovid Therapeutics Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Ovid Therapeutics Inc. has 184.76M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 208.87, and the price-to-book ratio stands at 2.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 251.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 348.25M versus a market cap of 439.72M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ovid Therapeutics Inc. maintains a current ratio of 12.39, meaning it holds 12.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Ovid Therapeutics Inc. posted a negative return on equity (ROE) of -25.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -22.30, reflecting losses generated across the asset base. The company generates approximately 60,243.47 in revenue per employee across its workforce of 23.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Ovid Therapeutics Inc.'s stock has gained approximately 58.52% over the past 52 weeks. The 50-day moving average sits at 2.27, while the 200-day moving average is 2.03.

Over the twelve months ended June 30, 2026, Ovid Therapeutics Inc. generated 1.39M in revenue and converted that into -30.19M in net income, yielding earnings per share of -0.25. EBITDA reached -51.01M, while operating income came in at -51.08M.

As of June 30, 2026, Ovid Therapeutics Inc. holds 102.60M in cash and equivalents against 11.13M in total debt, resulting in a net debt position of -9.91M. Total book value stands at 183.72M, with working capital of 99.47M providing operational flexibility.

Ovid Therapeutics Inc. produced -47.94M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -47.94M - equivalent to -0.39 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -3,686.67 and net profit margin of -2,178.90 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -36.98, meaning Ovid Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Ovid Therapeutics Inc. has an Altman Z-Score of 11.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.